Efficacy of collagenase Clostridium histolyticum combination therapies for Peyronie's disease: a systematic review and meta-analysis

Yicheng Guo,Yingying Yang,Qiancheng Mao,Hongquan Liu,Tianqi Wang,Fengze Sun,Jitao Wu,Yuanshan Cui

DOI: https://doi.org/10.1093/sxmrev/qeae025

2024-04-24

Sexual Medicine Reviews

Abstract:Introduction Peyronie's disease (PD) is a common penile disorder characterized by the formation of fibrous noncompliant hard nodules in the tunica albuginea of the penis. Collagenase Clostridium histolyticum (CCH) is an injectable drug that treats PD by enzymatically degrading plaque interstitial collagen. CCH has been used in patients with varying curvature, as well as in the acute and stable phases of the disease, through a variety of treatment regimens and combinations. We carried out a systematic review and meta-analysis to assess the efficacy of CCH combination therapies for PD. Methods We selected 4 observational comparative studies and 3 randomized controlled trials including 532 participants from the PubMed, Embase, and Cochrane databases (until December 2023) to evaluate the efficacy of CCH combination therapies for PD. The primary outcome was clinical efficacy as evaluated by improvement in penile curvature and penile length, as well as by scores on the Peyronie's Disease Questionnaire (PDQ) for symptom bother, penile pain, and psychological symptoms. Continuous data were represented by mean difference (MD) and 95% CI. All data were analyzed by Review Manager version 5.3. Results For penile length (MD, 0.81 cm; 95% CI, 0.17-1.45; P = .01), PDQ symptom bother (MD, –1.02; 95% CI, –1.83 to –0.21; P = .01), and PDQ penile pain (MD, –0.93; 95% CI, –1.50 to –0.36; P = .001), CCH combination therapy showed significantly greater improvements vs CCH monotherapy. However, in the other indicators, penile curvature and PDQ psychological symptoms, there was no significant difference between the therapies. Conclusion This meta-analysis supports that CCH combination therapies can partially increase penile length and ameliorate symptom bother and penile pain to some extent. However, CCH combination therapies still need to be evaluated through more high-quality research.

urology & nephrology

What problem does this paper attempt to address?

### Problems the Paper Attempts to Solve

This paper aims to evaluate the efficacy of **collagenase clostridium histolyticum (CCH) combination therapy** in the treatment of **Peyronie's disease (PD)**. Peyronie's disease is a common male genital disorder characterized by the formation of fibrous plaques in the tunica albuginea of the penis, leading to penile curvature, pain, and erectile dysfunction. CCH is an injectable drug that treats Peyronie's disease by enzymatically degrading the collagen in the plaque matrix. Although CCH has been used in patients with different degrees of curvature and in both acute and stable phases of the disease, and with various treatment regimens and combination therapies, the specific efficacy of combination therapy still needs further evaluation.

### Research Background

1. **Characteristics of Peyronie's Disease**: Peyronie's disease is primarily caused by abnormal collagen deposition in the penile fibrous tissue, making it difficult to treat.
2. **Existing Treatment Methods**:
- **Surgical Treatment**: While surgery is effective, it carries high risks and may lead to side effects and complications.
- **Conservative Treatment**: Includes oral medications, injectable drugs, penile traction, and vacuum therapy, suitable for patients in the active or stable phase who are unwilling to undergo surgery. These methods have fewer side effects but limited efficacy.
3. **Mechanism of Action of CCH**: CCH degrades collagen in the plaque through enzymatic action and has shown good therapeutic effects, but its efficacy is limited when used alone.
4. **Potential of Combination Therapy**: Combining chemical drugs and mechanical therapies may have a synergistic effect, improving overall treatment outcomes.

### Research Objectives

To evaluate the clinical efficacy of CCH combination therapy in the treatment of Peyronie's disease through a systematic review and meta-analysis, particularly in terms of improving penile curvature, increasing penile length, and alleviating symptom distress, penile pain, and psychological symptoms.

### Research Methods

1. **Literature Search**: Relevant literature was searched from PubMed, Embase, and Cochrane databases, with a time frame up to December 2023.
2. **Inclusion Criteria**: Selected 4 observational comparative studies and 3 randomized controlled trials, with a total of 532 participants.
3. **Primary Outcome Measures**: Included improvement in penile curvature and length, as well as symptom distress, penile pain, and psychological symptoms as measured by the Peyronie's Disease Questionnaire (PDQ).
4. **Data Analysis**: Data were processed using Review Manager 5.3, with continuous data analyzed using fixed-effect or random-effect models.

### Main Results

1. **Penile Length**: CCH combination therapy significantly increased penile length (MD 0.81 cm, 95% CI 0.17-1.45, P=0.01).
2. **PDQ Symptom Distress Score**: CCH combination therapy significantly improved symptom distress (MD -1.02, 95% CI -1.83 to -0.21, P=0.01).
3. **PDQ Penile Pain Score**: CCH combination therapy significantly improved penile pain (MD -0.93, 95% CI -1.50 to -0.36, P=0.001).
4. **Penile Curvature**: CCH combination therapy did not significantly improve penile curvature (MD 0.99°, 95% CI -5.60° to 7.57°, P=0.77).
5. **PDQ Psychological Symptoms Score**: CCH combination therapy did not show significant advantages in psychological symptoms (MD -1.69, 95% CI -3.95 to 0.57, P=0.14).

### Conclusion

This meta-analysis supports the efficacy of CCH combination therapy in partially increasing penile length and improving symptom distress and penile pain. However, more high-quality studies are needed to further evaluate CCH combination therapy.